ACM
IHE icon

Anfield Capital Management’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Anfield Capital Management’s Portfolio IHE Stock Details IHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.2M Buy
129,577
+11,612
+10% +$1.02M 3.09% 7
2025
Q4 		$10M Buy
+117,965
New +$9.41M 3.16% 6

Other funds holding IHE

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
FIA
Foundations Investment Advisors Phoenix, Arizona $9.72B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
ACA
Aptus Capital Advisors Fairhope, Alabama $14.6B AUM 22.78% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
IWS
Insight Wealth Strategies San Ramon, California $1.02B AUM 38% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Anfield Capital Management's IHE Position: Q1 2026 in Review

Anfield Capital Management increased its iShares US Pharmaceuticals ETF (IHE) stake by 9.8% in Q1 2026, buying an estimated $1.02M and bringing the position to 129,577 shares worth $11.2M. The position accounts for 3.09% of the portfolio, ranked #7.

Anfield Capital Management first reported a position in IHE in Q4 2025 and has held it in 2 quarters since. 194 funds tracked by Wall St. Rank hold IHE as of Q1 2026.

  • Anfield Capital Management held 129,577 shares of iShares US Pharmaceuticals ETF worth $11.2M as of Q1 2026.
  • Anfield Capital Management bought 11,612 iShares US Pharmaceuticals ETF shares in Q1 2026, an estimated $1.02M.
  • iShares US Pharmaceuticals ETF made up 3.09% of Anfield Capital Management's portfolio in Q1 2026, its #7 holding.
  • Anfield Capital Management first reported a position in iShares US Pharmaceuticals ETF in Q4 2025 and has held it in 2 quarters since.
  • 194 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q1 2026.

Based on Anfield Capital Management's 13F filing for Q1 2026, filed 12 May 2026.